Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues. …
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
New Stories
-
New Zealand's Medsafe and Pharmac directed to explore AI use to expedite access
July 2, 2025 - - Latest News -
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 - - Latest News -
Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer
July 2, 2025 - - Latest News -
The industry backs productivity focus for the Albanese Government's second term
July 2, 2025 - - Latest News -
Wesfarmers Health launches pilot pharmacy format, InstantScripts Pharmacy Health Hub
July 2, 2025 - - Latest News -
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News